Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials
Amaia Eleonora Maennling1, Mehmet Kemal Tur2,3, Marcus Niebert4
1Department of Gynecology and Obstetrics, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany.
Abstract:
：The epidermal growth factor receptor (EGFR) family contains four transmembrane tyrosine kinases (EGFR1/ErbB1, Her2/ErbB2, Her3/ErbB3 and Her4/ErbB4) and 13 secreted polypeptide ligands. EGFRs are overexpressed in many solid tumors, including breast, pancreas, head-and-neck, prostate, ovarian, renal, colon, and non-small-cell lung cancer. Such overexpression produces strong stimulation of downstream signaling pathways, which induce cell growth, cell differentiation, cell cycle progression, angiogenesis, cell motility and blocking of apoptosis.The high expression and/or functional activation of EGFRs correlates with the pathogenesis and progression of several cancers, which make them attractive targets for both diagnosis and therapy. Several approaches have been developed to target these receptors and/or the EGFR modulated effects in cancer cells. Most approaches include the development of anti-EGFRs antibodies and/or small-molecule EGFR inhibitors. This review presents the state-of-the-art and future prospects of targeting EGFRs to treat breast cancer.
Insights
Epidermal growth factor receptor (EGFR) targeting is crucial for treating various cancers. This review focuses on state-of-the-art and future prospects of using anti-EGFR therapies for breast cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- The epidermal growth factor receptor (EGFR) family comprises four tyrosine kinases and 13 ligands.
- EGFRs are overexpressed in numerous solid tumors, driving cancer progression.
- EGFR overexpression stimulates pathways involved in cell growth, angiogenesis, and metastasis.
Purpose of the Study:
- To review the current strategies for targeting EGFRs in cancer therapy.
- To highlight the state-of-the-art and future directions for EGFR-targeted breast cancer treatment.
Main Methods:
- Review of existing literature on EGFR family, overexpression, and targeted therapies.
- Analysis of current anti-EGFR antibodies and small-molecule inhibitors.
- Discussion of diagnostic and therapeutic approaches targeting EGFRs.
Main Results:
- EGFRs are validated targets due to their correlation with cancer pathogenesis and progression.
- Multiple therapeutic strategies, including antibodies and small-molecule inhibitors, have been developed.
- Targeting EGFRs offers a promising avenue for cancer treatment, particularly breast cancer.
Conclusions:
- EGFRs play a significant role in the development and progression of various cancers.
- Targeted therapies against EGFRs are essential for effective cancer treatment.
- Future research should focus on advancing EGFR-targeted strategies for improved breast cancer outcomes.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
07:33Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
Published on: September 19, 2025
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...